This consensus statement provides information on novel minimally invasive therapeutic interventions for thyroid malignancies such as percutaneous ethanol injection and thermal ablation. The statement summarizes existing knowledge and provides guidance on indications, techniques, complications, and follow-ups for care of patients with benign and malignant thyroid lesions.
This consensus statement describes the Thyroid Nodule App (termed TNAPP), a novel interactive web-based tool that uses clinical, imaging, cytologic, and molecular marker data to guide clinical decision making to evaluate and manage thyroid nodules.
This consensus statement outlines expert opinion and practical information on the evaluation of thyroid nodules, surgical considerations, and postoperative monitoring for children and adolescents with benign and malignant thyroid lesions.
The AACE Journey for Patients With Thyroid Disease is a reliable resource to help your patients better understand and manage their condition. Developed from our clinical guidance documents and reviewed by the Thyroid Cancer Survivors’ Association (ThyCa), it provides accurate, patient-centered information.
Read MoreWatch our free on-demand webinar sponsored by Immunovant, Inc., to hear from clinical experts Mark Lupo, MD, founder and medical director of the Thyroid & Endocrine Center of Florida, and Giuseppe Barbesino, MD, of Massachusetts General Hospital, for a moderated discussion about the treatment landscape in Graves’ disease, which has remained largely unchanged for the last 70 years.
Read MoreHelp your patients better understand thyroid conditions and treatment options by sharing our AACE Thyroid Playlist on YouTube, a trusted resource for reliable thyroid health education.
Learn More